Aarkstore - Febrile Neutropenia-Pipeline Insights, 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Febrile Neutropenia-Pipeline Insights, 2014

Description:

DelveInsights, Febrile Neutropenia-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Febrile Neutropenia. – PowerPoint PPT presentation

Number of Views:149

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Febrile Neutropenia-Pipeline Insights, 2014


1
Febrile Neutropenia-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/77059/-febrile
    -neutropenia-pipeline-insights-2014

2
Summary
  • DelveInsights, Febrile Neutropenia-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication. A key objective of the report is to
    establish the understanding for all the pipeline
    drugs that fall under Febrile Neutropenia. This
    report provides information on the therapeutic
    development based on the Febrile Neutropenia
    dealing with all the pipeline drugs, comparative
    analysis at various stages covering Filed, Phase
    III, Phase II, Phase I, IND filed, Preclinical,
    Discovery and unknown stages, therapeutics
    assessment by monotherapy and combination
    products and molecule type drug information. The
    report also covers the companies information
    involved in the therapeutic development of the
    products. It also has highlighted the
    discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Note This report requires
    certain updates. We have all the information
    available but require 3 business days to complete
    the process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated Indication.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Febrile NeutropeniaThe
    report provides pipeline products under drug
    profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the Febrile Neutropenia
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    typeThe report reviews key players involved in
    the therapeutics development for Febrile
    Neutropenia and also provide company
    profilingThe report also gives the information
    of dormant and discontinued pipeline
    projects Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete Pipeline intelligence
    and complete understanding over therapeutics
    development for Febrile Neutropenia
  • Identify the relationship between the drugs and
    use it for target finding, drug repurposing, and
    precision medicine.
  • Devise corrective measures for pipeline projects
    by understanding Febrile Neutropenia pipeline
    depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your
    drug development activities.
  • Optimize your portfolio and keep you in touch
    with the rapidly changing pharmaceutical markets,
    and make the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies
  • Modify the therapeutic portfolio by identifying
    discontinued projects and understanding the
    factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive
    Landscape for Evidence based Decisions
  • You can order full Report with TOC and for Sample
    page visit _at_
  • http//www.aarkstore.com/healthcare/77059/-febril
    e-neutropenia-pipeline-insights-2014

7
Table of Content
  • Febrile Neutropenia OverviewFebrile Neutropenia
    Pipeline TherapeuticsFebrile Neutropenia
    Therapeutics under Development by
    Companies Febrile Neutropenia Late Stage
    Products (Filed and Phase III)Comparative
    Analysis Febrile Neutropenia Mid Clinical Stage
    Products (Phase II)Comparative Analysis Febrile
    Neutropenia Early Clinical Stage Products (Phase
    I and IND Filed)Comparative Analysis Febrile
    Neutropenia Discovery and Pre-Clinical Stage
    Products Comparative Analysis Drug Candidate
    Profiles

8
Table of Content
  • Febrile Neutropenia Therapeutics
    Assessment Assessment by Monotherapy
    Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type Febrile Neutropenia Discontinued
    Products Febrile Neutropenia Dormant
    ProductsCompanies Involved in Therapeutics
    Development for Febrile Neutropenia Appendix Met
    hodology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for Febrile
    Neutropenia, 2014Number of Products under
    Development by Companies Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014Drug Candidates ProfilesFebrile Neutropenia
    Assessment by Monotherapy Products Febrile
    Neutropenia Assessment by Combination Products 

10
List of Tables
  • Febrile Neutropenia Assessment by Route of
    Administration Febrile Neutropenia Assessment by
    Stage and Route of Administration Febrile
    Neutropenia Assessment by Molecule Type Febrile
    Neutropenia Assessment by Stage and Molecule
    Type Febrile Neutropenia Therapeutics
    Discontinued Products Febrile Neutropenia
    Therapeutics Dormant ProductsProducts under
    Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Febrile
    Neutropenia, 2014Late Clinical Stage Products
    (Filed and Phase III), 2014Mid Clinical Stage
    Products (Phase II), 2014Early Clinical Stage
    Products (Phase I and IND Filed), 2014Discovery
    and Pre-Clinical Stage Products, 2014Febrile
    Neutropenia Assessment by Monotherapy
    Products Febrile Neutropenia Assessment by
    Combination Products Febrile Neutropenia
    Assessment by Route of Administration Febrile
    Neutropenia Assessment by Stage and Route of
    Administration Febrile Neutropenia Assessment by
    Molecule Type Febrile Neutropenia Assessment by
    Stage and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Febrile Neutropenia-Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights, Febrile Neutropenia-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication.
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com